None listed
Conditions
Interventions
Drug : Patients with major depressive disorder with physical symptoms selected according to inclusion criteria and exclusion criteria would be randomly assigned to the placebo (control) and "
Aripiprazole"
(experimental) groups. The aripiprazole group will receive Aripiprazole for 8 weeks, starting with 2 mg of Aripiprazole daily, increasing to 10 mg depending on symptoms and side effects. The placebo g
Sponsors
Chung-Ang Univerisity Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Age between 20 and 65 years old ? Patients diagnosed with major depressive disorder not accompanied by psychotic symptoms by Structured Clinical Interview for DSM-5 (SCID-5) ? 11 or more points on the SCL-90R-SOM scale, meaning accompanying significant somatic symptoms. ? Those who have no history of using antipsychotics, including aripiprazole, at the time of initial evaluation ? Those who are taking antidepressants at stable dose for more than 1 month
Exclusion criteria
Exclusion criteria: ? Those who have been diagnosed with other psychiatric disorder by SCID-5-CV ? People with past or present substance dependence or abuse history ? A person with a history of epilepsy, head trauma, or organic mental illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom Check List-90-Revised-Somatization (SCL-90-R-SOM) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Theta coherence of Quantitative Electroencephalogram (QEEG) | — |
Countries
Korea, Republic of
Contacts
Public ContactHee Jin Kim
Chung-Ang Univerisity Hospital
Outcome results
None listed